Researchers presented results from the randomized controlled trial of mPATH-Lung at the CHEST Annual Meeting. Eric Singhi, MD, discusses the key milestone that will be celebrated at the conference, which will be held in San Diego. Learn how clinicians can take practical steps to ensure patients with lung cancer receive comprehensive biomarker testing. Recent data show that less than half of patients are receiving biomarker testing results before starting treatment. The initiative aims to increase biomarker testing rates in communities most impacted by lung cancer disparities. Lurbinectedin monotherapy is currently being studied in Jazz EMERGE 402 study in patients with metastatic SCLC. Patients with autoimmune diseases—including rheumatoid arthritis (RA)—do not have poorer lung cancer survival ...